抗感染剤の世界市場:類型別 (抗細菌、抗真菌、抗ウイルス)、投与ルート別(経口、局所、静注)、流通チャネル別

Grand View Researchが発行した調査報告書(GV905011)
◆英語タイトル:Anti-infective Agents Market Size, Share & Trend Analysis By Type (Antibacterial, Antifungal, Antiviral), By Route of Administration (Oral, Topical, IV), By Distribution Channel, And Segment Forecasts, 2019 - 2026
◆商品コード:GV905011
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2019年3月25日◆ページ数:190
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:Pharmaceuticals
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi UserUSD5,950 ⇒換算¥880,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD7,950 ⇒換算¥1,176,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、抗感染剤の世界市場について調査・分析し、抗感染剤の世界市場動向、抗感染剤の世界市場規模、市場予測、セグメント別抗感染剤市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global anti-infective agents market size is expected to reach over USD 144.8 billion by 2026 according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 3.4% during the forecast period. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.
Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongstpeople regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.

Further key findings from the report suggest:

• Antiviral was estimated to be the largest segment with a market share of 48.8% in 2018 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV

• Antibacterial segment is anticipated to register the fastest CAGR of 4.0% during the forecast period, as antibacterial is the first line of treatment for a large range of infections. Increased prescription and accessibility of antibacterial due to their over-the-counter status is anticipated to further drive the segment

• Development of combination drugs to treat and prevent serious and life-threatening infections is expected to propel the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, a comprehensive treatment regimen inclusive of four drugs (cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record

• Oral route of administration was estimated to be the largest segment in 2018 owing to new product development and presence of strong product pipeline

• Hospital pharmacy led the anti-infective agents market in 2018 while e-commerce is expected to be the fastest growing segment during the forecast period

• North America was one of the leading regions in terms of revenue in 2018. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers

• Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients

• Some of the major companies operating in this market are Abbott; Gilead Sciences, Inc.; Bristol-Myers Squibb Company; Merck & Co., Inc.; Bayer AG; AstraZeneca; Boehringer Ingelheim; and Novartis AG.

• Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in 2015, ReViral received funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.

【レポートの目次】

Table of Content

Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Market definition
1.3. Information procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources & third-party perspectives
1.3.4. Primary research
1.4. Information analysis
1.4.1. Data analysis models
1.5. Market formulation & data visualization
1.6. Data validation & publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Global Anti-infective Agents Market Variables, Trends & Scope
3.1. Anti-infective agents Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Pipeline Analysis
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.1.1. Growing geriatric population base
3.4.1.2. Growing prevalence of target diseases such as hospital acquired infections, STIs, and respiratory viruses
3.4.1.3. Increase in collaborative development efforts
3.4.2. Market Restraint Analysis
3.4.2.1. Development of multi-drug resistant organisms
3.4.2.2. High R&D cost
3.5. Anti-infective agents Market Analysis Tools
3.5.1. Industry Analysis – Porter’s
3.5.1.1. Supplier Power: Low due to large number of manufacturers
3.5.1.2. Buyer Power: Moderate due to availability of several generic products
3.5.1.3. Substitution Threat: High due to presence external substitutes
3.5.1.4. Threat from new entrant: Moderate due to high investments required in R&D and manufacturing
3.5.1.5. Competitive rivalry: High due to rigorous competition among key players
3.6. PESTEL Analysis
3.6.1. Political Landscape
3.6.2. Environmental Landscape
3.6.3. Social Landscape
3.6.4. Technology Landscape
3.6.5. Legal Landscape
3.7. Major Deals & Strategic Alliances Analysis
3.7.1. Joint Ventures
3.7.2. Mergers & Acquisitions
3.7.3. Licensing & Partnership
3.7.4. Technology Collaborations
3.7.5. Strategic Divestments
Chapter 4. Anti-infective Agents Market – Competitive Analysis
4.1. Recent developments & impact analysis, by key market participants
4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
4.3. Public Companies
4.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
4.3.2. Company Market Share/Ranking, by region
4.3.3. Competitive Dashboard Analysis
4.3.4. Market Differentiators
4.3.5. Synergy Analysis: Major Deals & Strategic Alliances
4.4. Private Companies
4.4.1. List of key emerging companies
4.4.2. Regional network map
4.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
Chapter 5. Anti-infective Agents Market: Type Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Type market share analysis, 2018 & 2026
5.3. Type Dashboard
5.4. Global Anti-infective agents Market, by Type, 2013 to 2026
5.5. Market Size & Forecasts and Trend Analyses, 2013 to 2026 for the following,
5.5.1. Antibacterial by drug class
5.5.1.1. Antibacterial market, 2013 – 2026 (USD Billion)
5.5.1.2. Cephalosporins
5.5.1.2.1. Cephalosporins market, 2013 – 2026 (USD Billion)
5.5.1.3. Penicillin
5.5.1.3.1. Penicillin market, 2013 – 2026 (USD Billion)
5.5.1.4. Fluoroquinolones
5.5.1.4.1. Fluoroquinolones market, 2013 – 2026 (USD Billion)
5.5.1.5. Macrolides
5.5.1.5.1. Macrolides market, 2013 – 2026 (USD Billion)
5.5.1.6. Carbapenem
5.5.1.6.1. Carbapenem market, 2013 – 2026 (USD Billion)
5.5.1.7. Others
5.5.1.7.1. Others market, 2013 – 2026 (USD Billion)
5.5.2. Antibacterial by route of administration
5.5.2.1. Topical
5.5.2.1.1. Topical market, 2013 – 2026 (USD Billion)
5.5.2.2. Oral
5.5.2.2.1. Oral market, 2013 – 2026 (USD Billion)
5.5.2.3. IV
5.5.2.3.1. IV market, 2013 – 2026 (USD Billion)
5.5.2.4. Others
5.5.2.4.1. Others market, 2013 – 2026 (USD Billion)
5.5.3. Antifungal by drug class
5.5.3.1. Antifungal market, 2013 – 2026 (USD Billion)
5.5.3.2. Azoles
5.5.3.2.1. Azoles market, 2013 – 2026 (USD Billion)
5.5.3.3. Echinocandins
5.5.3.3.1. Echinocandins market, 2013 – 2026 (USD Billion)
5.5.3.4. Polyenes
5.5.3.4.1. Polyenes market, 2013 – 2026 (USD Billion)
5.5.3.5. Others
5.5.3.5.1. Others market, 2013 – 2026 (USD Billion)
5.5.4. Antifungal by route of administration
5.5.4.1. Antifungal market, 2013 – 2026 (USD Billion)
5.5.4.2. Topical
5.5.4.2.1. Topical market, 2013 – 2026 (USD Billion)
5.5.4.3. Oral
5.5.4.3.1. Oral market, 2013 – 2026 (USD Billion)
5.5.4.4. IV
5.5.4.4.1. IV market, 2013 – 2026 (USD Billion)
5.5.4.5. Others
5.5.4.5.1. Others market, 2013 – 2026 (USD Billion)
5.5.5. Antiviral by route of administration
5.5.5.1. Antiviral market, 2013 – 2026 (USD Billion)
5.5.5.2. Topical
5.5.5.2.1. Topical market, 2013 – 2026 (USD Billion)
5.5.5.3. Oral
5.5.5.3.1. Oral market, 2013 – 2026 (USD Billion)
5.5.5.4. IV
5.5.5.4.1. IV market, 2013 – 2026 (USD Billion)
5.5.5.5. Others
5.5.5.5.1. Others market, 2013 – 2026 (USD Billion)
Chapter 6. Anti-infective Agents Market: Route of Administration Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Route of administration market share analysis, 2018 & 2026
6.3. Route of Administration Dashboard
6.4. Global Anti-infective agents Market, by Route of Administration, 2013 to 2026
6.5. Market Size & Forecasts and Trend Analyses, 2013 to 2026 for the following,
6.6. Topical
6.6.1. Topical market, 2013 – 2026 (USD Billion)
6.7. ‘Oral
6.7.1. Oral market, 2013 – 2026 (USD Billion)
6.8. Intravenous (IV)
6.8.1. IV market, 2013 – 2026 (USD Billion)
6.9. Others
6.9.1. Others market, 2013 – 2026 (USD Billion)
Chapter 7. Anti-infective Agents Market: Distribution Channel Estimates & Trend Analysis
7.1. Definitions & Scope
7.2. Distribution channel market share analysis, 2018 & 2026
7.3. Distribution Channel Dashboard
7.4. Global Anti-infective Agents Market, by Distribution Channel, 2013 to 2026
7.5. Market Size & Forecasts and Trend Analyses, 2013 to 2026 for the following,
7.6. Hospital Pharmacy
7.6.1. Hospital Pharmacy market, 2013 – 2026 (USD Billion)
7.7. Retail Pharmacy
7.7.1. Retail Pharmacy market, 2013 – 2026 (USD Billion)
7.8. Specialty Pharmacy
7.8.1. Specialty Pharmacy market, 2013 – 2026 (USD Billion)
7.9. E-commerce
7.9.1. E-commerce market, 2013 – 2026 (USD Billion)
7.10. Others
7.10.1. Others market, 2013 – 2026 (USD Billion)
Chapter 8. Anti-infective Agents Market: Regional Estimates & Trend analysis
8.1. Regional Market Snapshot
8.2. Regional Market Share and Leading Players, 2018
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
8.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
8.5. North America
8.5.1. North America market, 2013 – 2026 (USD Billion)
8.5.2. U.S.
8.5.2.1. U.S. market, 2013 – 2026 (USD Billion)
8.5.3. Canada
8.5.3.1. Canada market, 2013 – 2026 (USD Billion)
8.6. Europe
8.6.1. Europe market, 2013 – 2026 (USD Billion)
8.6.2. U.K.
8.6.2.1. U.K. market, 2013 – 2026 (USD Billion)
8.6.3. Germany
8.6.3.1. Germany market, 2013 – 2026 (USD Billion)
8.6.4. Spain
8.6.4.1. Spain market, 2013 – 2026 (USD Billion)
8.6.5. France
8.6.5.1. France market, 2013 – 2026 (USD Billion)
8.6.6. Italy
8.6.6.1. Italy market, 2013 – 2026 (USD Billion)
8.6.7. Russia
8.6.7.1. Russia market, 2013 – 2026 (USD Billion)
8.7. Asia Pacific
8.7.1. Asia Pacific market, 2013 – 2026 (USD Billion)
8.7.2. China
8.7.2.1. China market, 2013 – 2026 (USD Billion)
8.7.3. Japan
8.7.3.1. Japan market, 2013 – 2026 (USD Billion)
8.7.4. India
8.7.4.1. India market, 2013 – 2026 (USD Billion)
8.7.5. South Korea
8.7.5.1. South Korea market, 2013 – 2026 (USD Billion)
8.7.6. Singapore
8.7.6.1. Singapore market, 2013 – 2026 (USD Billion)
8.7.7. Australia
8.7.7.1. Australia market, 2013 – 2026 (USD Billion)
8.8. Latin America
8.8.1. Latin America market, 2013 – 2026 (USD Billion)
8.8.2. Brazil
8.8.2.1. Brazil market, 2013 – 2026 (USD Billion)
8.8.3. Mexico
8.8.3.1. Mexico market, 2013 – 2026 (USD Billion)
8.8.4. Argentina
8.8.4.1. Argentina market, 2013 – 2026 (USD Billion)
8.9. Middle East Africa (MEA)
8.9.1. MEA market, 2013 – 2026 (USD Billion)
8.9.2. South Africa
8.9.2.1. South Africa market, 2013 – 2026 (USD Billion)
8.9.3. Saudi Arabia
8.9.3.1. Saudi Arabia market, 2013 – 2026 (USD Billion)
8.9.4. UAE
8.9.4.1. UAE market, 2013 – 2026 (USD Billion)
Chapter 9. Company Profiles
9.1. Strategic Framework
9.1.1. GlaxoSmithKline plc.
9.1.1.1. Company overview
9.1.1.2. Financial framework
9.1.1.3. Product benchmarking
9.1.1.4. Strategic initiatives
9.1.2. Pfizer, Inc
9.2.1.1. Company overview
9.2.1.2. Financial framework
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.1.3. Bayer AG
9.3.1.1. Company overview
9.3.1.2. Financial framework
9.3.1.3. Product benchmarking
9.3.1.4. Strategic initiatives
9.1.4. Sanofi
9.4.1.1. Company overview
9.4.1.2. Financial framework
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.1.5. Merck & Co., Inc.
9.5.1.1. Company overview
9.5.1.2. Financial framework
9.5.1.3. Product benchmarking
9.5.1.4. Strategic initiatives
9.1.6. Bristol-Myers Squibb Company
9.6.1.1. Company overview
9.6.1.2. Financial framework
9.6.1.3. Product benchmarking
9.6.1.4. Strategic initiatives
9.1.7. Abbott
9.7.1.1. Company overview
9.7.1.2. Financial framework
9.7.1.3. Product benchmarking
9.7.1.4. Strategic initiatives
9.1.8. Novartis AG
9.8.1.1. Company overview
9.8.1.2. Financial framework
9.8.1.3. Product benchmarking
9.8.1.4. Strategic initiatives
9.1.9. Johnson & Johnson Services, Inc
9.9.1.1. Company overview
9.9.1.2. Financial framework
9.9.1.3. Product benchmarking
9.9.1.4. Strategic initiatives
9.1.10. Astellas Pharma Inc
9.10.1.1. Company overview
9.10.1.2. Financial framework
9.10.1.3. Product benchmarking
9.10.1.4. Strategic initiatives
9.1.11. Gilead Sciences, Inc.
9.11.1.1. Company overview
9.11.1.2. Financial framework
9.11.1.3. Product benchmarking
9.11.1.4. Strategic initiatives

...

【掲載企業】

GlaxoSmithKline plc., Pfizer, Inc, Bayer AG, Sanofi, Merck & Co., Inc., Bristol-Myers Squibb Company, Abbott, Novartis AG, Johnson & Johnson Services, Inc, Astellas Pharma Inc, Gilead Sciences, Inc.

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 抗感染剤の世界市場:類型別 (抗細菌、抗真菌、抗ウイルス)、投与ルート別(経口、局所、静注)、流通チャネル別(Anti-infective Agents Market Size, Share & Trend Analysis By Type (Antibacterial, Antifungal, Antiviral), By Route of Administration (Oral, Topical, IV), By Distribution Channel, And Segment Forecasts, 2019 - 2026)]についてメールでお問い合わせはこちらでお願いします。